AG
TNGX icon

Artal Group’s Tango Therapeutics TNGX Stock Holding History

Artal Group’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,519,841
Closed -$21.6M – 90
2024
Q2 		$21.6M Buy
2,519,841
+325,000
+15% +$2.51M 0.55% 24
2024
Q1 		$17.4M Buy
+2,194,841
New +$23.5M 0.44% 29

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group's TNGX Position: Q3 2024 in Review

Artal Group sold out of Tango Therapeutics (TNGX) in Q3 2024, closing a stake of 2,519,841 shares — an estimated $21.6M sold.

Artal Group first reported a position in TNGX in Q1 2024 and held it in 2 quarters. The position peaked at $21.6M in Q2 2024. 121 funds tracked by Wall St. Rank hold TNGX as of Q3 2024.

  • Artal Group reported no remaining Tango Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 2,519,841 Tango Therapeutics shares in Q3 2024, an estimated $21.6M.
  • Artal Group first reported a position in Tango Therapeutics in Q1 2024 and held it in 2 quarters.
  • Artal Group's Tango Therapeutics position peaked at $21.6M in Q2 2024.
  • 121 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.